Cardiology Daily Report: 01/17/2024

A prospective cohort study, the NARDI-ACS study, evaluated the diagnostic ability of serum nardilysin (NRDC) for early detection of ACS (1). The study included 435 patients in the Phase I cohort and 486 in the Phase II cohort. NRDC had higher sensitivity than hsTnI within 6 hours of onset, and its combined use with hsTnI improved early diagnosis of ACS.

Reference

Ohno M, Shiomi H, Baba O, Yano M, Aizawa T, Nakano-Matsumura Y, Yamagami S, Kato M, Ohya M, Chen PM, Nagao K, Ando K, Yokomatsu T, Kadota K, Kouchi I, Inada T, Valentine C, Kitagawa T, Kurokawa M, Ohtsuru S, Morimoto T, Kimura T, Nishi E. Auxiliary roles of nardilysin in the early diagnosis of acute coronary syndrome: a prospective cohort study, the Nardi-ACS study. Intern Emerg Med. 2024 Jan 17. doi: 10.1007/s11739-023-03508-0. Epub ahead of print. PMID: 38233578.